Postpartum depression affects as many as 400,000 women in the United States every year, and on Tuesday, the Food and Drug Administration approved the first drug specifically created to treat the disorder. Brexanolone, also known as Zulresso, is delivered intravenously. The infusion takes 60 hours, and during a clinical trial, most participants showed improvement within 24 hours of receiving the drug, reporting they still felt the effects 30 days later. Brexanolone contains a synthetic form of allopregnanolone, a derivative of progesterone, which increases during pregnancy and drops dramatically after giving birth. It is thought allopregnanolone could contribute to postpartum depression.

Scroll for 5 things you
need to know now